Navigation Links
Insmed to Seek Shareholder Approval for Reverse Split

RICHMOND, Va., Oct. 14 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq CM: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it will seek shareholder approval to implement a reverse stock split, if necessary, at a Special Meeting of Stockholders on November 24, 2008, in an effort to meet the minimum bid price rule for continued listing on The NASDAQ Stock Market.

On September 3, 2008, the Company announced that the NASDAQ Listing Qualifications Panel had granted Insmed's request to remain listed on The NASDAQ Stock Market, subject to the condition that on or before December 15, 2008, Insmed must evidence a closing bid price of $1.00 or more for a minimum of ten consecutive business days (the "Minimum Bid"). The process for formally seeking shareholder approval for a reverse split takes several weeks and, therefore, needs to be initiated at this time so that it can be in place, if needed, to meet the December 15, 2008 compliance deadline. If Insmed is able to attain the Minimum Bid by the compliance deadline without the need for a reverse stock split, the Company may choose not to effect the split.

"Insmed, in conjunction with RBC Capital Markets, continues to work diligently to secure an appropriate partner for our follow-on biologics business," said Geoffrey Allan, President and CEO of Insmed. "Given that we are not able to determine the exact timing and potential impact of a partnership on our share price at this time, we felt it was prudent to take the necessary steps to enable us to execute a reverse split, should we need to, in order to maintain our listing on NASDAQ. Given the current economic climate, we believe being a NASDAQ-listed company and having access to the capital markets is necessary."

The date for determining stockholders of record entitled to receive notice of, and to vote at, the Special Meeting is October 17, 2008. A definitive proxy statement containing important stockholder information regarding the proposed reverse stock split will be mailed to all stockholders on or about October 31, 2008. Copies of the proxy statement will also be available at no charge from the Securities and Exchange Commission's website at Stockholders are urged to read the proxy statement prior to submitting their vote.

As of October 10, 2008, there were 122,315,635 shares of Insmed common stock outstanding. The reverse stock split would affect all Insmed common stock and stock options outstanding immediately prior to the effective time of the reverse stock split, if approved.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that strategic alternatives may never be consummated, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, we may be unable to secure an appropriate business partner for our follow-on biologics business, our common stock could be delisted from The NASDAQ Capital Market and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD


Corporate Communications Contact:

John Procter - Gibraltar Associates


SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader SAP and ... to develop and pitch their BIG ideas to improve health and wellness in their ... votes to win the title of SAP's Teen Innovator, an all-expenses paid trip to ...
Breaking Biology Technology:
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... announced that Google has adopted the Synaptics ® ... solutions to power its newest flagship smartphones, the Nexus ... --> --> ... to provide strategic collaboration in the joint development of ...
(Date:10/26/2015)... 2015  Delta ID Inc., a company focused on ... PC devices, announced its ActiveIRIS® technology powers the iris ... launched by NTT DOCOMO, INC in Japan ... smartphone to include iris recognition technology, after a very ... in May 2015, world,s first smartphone to have this ...
(Date:10/22/2015)...  Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter ended September 30, 2015.  --> ... $4.0 million, a decrease of 33% compared to $6.0 million in ... of 2015 was $2.2 million, or $0.10 per diluted share, which ... same period a year ago.  --> ...
Breaking Biology News(10 mins):